Figure 4

Knock down of AEG-1 sensitized cells to cisplatin and doxorubicin. M17 and SK-N-SH cells were transfected with AEG-1 siRNA1 or control siRNA for 48 h, then exposed to various concentrations of cisplatin or doxorubicin for 48 h, and the viability was accessed. The percentage of cell growth was calculated by comparison of the A570 reading from treated cells versus control cells. The IC₅₀ value of M17 cells to cisplatin (A) and doxorubicin (B) was 6.4 and 3.4 μM, respectively. The IC₅₀ values of SK-N-SH cells to cisplatin (C) and doxorubicin (D) were 3.3 and 2.8 μM, respectively. These results demonstrated that transfection of AEG-1 siRNA1 increased the sensitivity of M17 and SK-N-SH to cisplatin by 4.3- and 4.5-fold and to doxorubicin by 1.9- and 2.3-fold, respectively. Each experiment was performed three times in triplicate.